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MEDICATION ADHERENCE AND PERSISTENCE OF CLOPIDOGREL IN 
ACUTE CORONARY SYNDROME PATIENTS WITH AND WITHOUT 
DIABETES MELLITUS
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OBJECTIVES: The recent ACC/AHA guidelines recommend the use of clopidogrel for 
at least 1 year in ACS-PCI patients who are not at high risk of bleeding. However, 
use of clopidogrel may not meet this guidance due to compliance issues. In this study, 
1-year compliance of clopidogrel by ACS patients with or without diabetes mellitus 
(DM) was studied. METHODS: A total of N  12,502 ACS patients, aged 18–64 
years and hospitalized with a primary diagnosis of ACS between January 1, 2005 and 
December 31, 2006 were identiﬁed with complete 1-year follow-up eligibility and drug 
use information in the MarketScan claims database. Patients were categorized into 
two cohorts: DM (N  3040) and non-DM (N  9462). Adherence was measured by 
the medication possession ratio (MPR). Persistence was reported using the time from 
index hospitalization to the ﬁrst gap of 30 days between exhausting the supplied 
medication and ﬁlling the next prescription. Adherence and persistence between 
cohorts was compared using propensity score-adjusted bootstrapping method. 
RESULTS: A total of 72.1% (2193/3040) DM patients and 76.1% (7197/9462, p  
0.01) non-DM patients had at least 1 outpatient ﬁll for clopidogrel in the 1-year after 
the index hospitalization. Among the clopidogrel users (64.9% PCI, 30.8% medical 
management, 4.3% CABG), the average MPR was 0.78 for DM patients and 0.80 for 
non-DM patients (p  0.189). Signiﬁcantly lower persistence was observed for DM 
patients vs. non-DM patients (257.6 vs. 274.7 days, p  0.012). ACS patients undergo-
ing PCI had signiﬁcantly higher persistence compared to medical management patients 
(280.7 vs. 231.4 days, p  0.001 for DM; 285.7 vs. 254.6 days, p  0.001 for non-
DM). CONCLUSIONS: Approximately three-fourths of patients in this study had 
used clopidogrel after being hospitalized for ACS. ACS patients with prior diabetic 
history were less likely to be persistent with medication than non-diabetic ACS 
patients. This ﬁnding might have clinical consequences since DM patients typically 
have higher risk of cardiac events.
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OBJECTIVES: In the contemporary world, particularly in developing countries, car-
diovascular (CV) diseases are a major health care problem. Agents acting on the 
renin-angiotensin system (RAS) have an important place in the management of these 
diseases. METHODS: The data concerning drugs usage prescribed by GPs during the 
period from 2001 to 2007 were collected from the Croatian Health Insurance Institute. 
Annual volumes of drugs are presented in deﬁned daily doses/1000 inhabitants/day 
(DDD/1000), while ﬁnancial expenditure data are presented in Euros (a). An average 
cost per DDD was calculated for this group of drugs. RESULTS: Agents acting on the 
RAS for the seven-year period remained the most prescribed CV drug group with 
the largest cost share. The use of the whole group increased 115% (from 56.07 to 
120.55 DDD/1000) while the related expenses increased 53.5%. The consumption 
and cost shares of ACE inhibitors (plain and combined) decreased (from 98% to 88% 
and from 96% to 90%, respectively). The use of the combinations of ACE inhibitors 
and diuretics increased from 10.07 to 41.90 DDD/1000 and angiotensin receptor 
blockers and diuretics from 0 to 6.42 DDD/1000. The average cost per DDD for the 
investigated group dropped from 0.33 to 0.24 a/DDD. CONCLUSIONS: During the 
investigated period the usage of the group of agents acting on the RAS increased con-
siderably. The related growth of ﬁnancial expenditure increased at a slower rate. The 
average cost per DDD gradually decreased mainly as the result of the introduction of 
generics and the implementation of restrictive measures on the Croatian drug 
market.
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OBJECTIVES: This study compared the real-world practice patterns for ACS patients 
with and without DM in a large privately insured population. METHODS: A retro-
spective cohort study was conducted using the MarketScan claims database. Patients 
aged 18–65 years (N  22,693), hospitalized with a primary diagnosis of ACS between 
January 2005 and December 2006 were categorized into 2 groups: with DM (N  
6,049) and without DM (N  16,644). Patient characteristics, treatment patterns 
during the index-hospitalization and cardiovascular medications use 12-month pre- 
and post-index hospitalization were analyzed. Results had p  0.0001 unless otherwise 
stated. RESULTS: Patients with DM were more likely to be older (56.2 vs. 54.5), 
female (33.7% vs. 26.6%) and have higher rates of previous MI (14.5% vs. 10.5%), 
congestive heart failure (13.5% vs. 3.2%), PAD (9.9% vs. 3.7%), TIA/stroke (4.8% 
vs. 2.0%), hypertension (53.1% vs. 34.1%), hyperlipidemia (42.3% vs. 30.8%) and 
renal diseases (8.5% vs. 1.2%). During the index-hospitalization, patients with DM 
underwent less PCI (42% vs. 51.7%), more CABG (11.6% vs. 8.2%), and were more 
likely to be medically managed (46.3% vs. 40.1%). More ACE inhibitors (pre: 40.6% 
vs. 15.5%; post: 65.2% vs. 60.5%), beta blockers (pre: 38.4% vs. 21.8%; post: 88.4% 
vs. 85.9%) were prescribed to patients with DM both in the pre- and post-index hos-
pitalization period. While more statins (59.6% vs. 30%) and thienopyridine (14.6% 
vs. 6.4%) were prescribed to patients with DM in the pre-period, in the post-period 
statin use was similar for patients in both groups (89.1% vs. 88.0%, p  0.11) and 
thienopyridine use was less frequent in patients with DM (72.1% vs. 75.9%) possibly 
due to higher rates of CABG. CONCLUSIONS: Patients with DM had a less-favorable 
comorbidity proﬁle, underwent less PCI but more CABG and were more likely to have 
medical management during the index hospitalization. Hospitalization with ACS 
shifted the usage pattern of cardiovascular medications.
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OBJECTIVES: To describe health care resources utilization and health related quality          
of life over 12 months in patients with acute coronary syndrome (ACS) undergoing 
percutaneous coronary intervention (PCI) in France. METHODS: This prospective,  
international observational study recruited ACS patients undergoing PCI in 2007–08, 
capturing practice patterns, resources use and HRQoL over 12 months. Interventional 
cardiologists collected data from ACS events to hospital discharge, and primary care 
physicians (PCP) and cardiologists collected follow-up data. RESULTS: A total of 483 
ACS-PCI patients, median age 59 years (Q1-Q3 52–71), median weight 79 kg (Q1-Q3 
70–90), 18% female, 47% with ST-elevation MI (STEMI) and 53% with unstable 
angina or non-ST-elevation MI (UA/NSTEMI) were recruited in France. Almost all   
patients (96%) received stents: 67% bare metal stents (BMS), 23% drug eluting stents 
(DES) and 11% both. Median total length of hospital stay was 6 (Q1-Q3 4–8) days.           
Follow-up data on post discharge resource use up to 12 months are available for 394 
(82%) patients. At discharge, these patients were receiving clopidogrel-94%, aspirin-
95%, statins-82%, beta-blockers-82%, ACE inhibitors/ARBs-68%. During the year     
following PCI, patients had on average 7.7 (SD  4.7) visits to PCPs, 3.1(SD  1.7) 
visits to cardiologists, and STEMI and UA/NSTEMI patients had the same number of 
visits to physicians. 6% of patients had planned hospital re-admissions: 8% for STEMI 
patients and 4% for UA/NSTEMI patients. 14% of patients had hospital re-admissions 
related to a cardiovascular event: 11% for STEMI patients and 16% for UA/NSTEMI 
patients. Mean change of EuroQol VAS between discharge and 1 year was 18.2 (SD 
 30.4), respectively 18.1(SD  30.0) for STEMI patients and 18.3 (SD  30.9) for 
UA/NSTEMI patients. CONCLUSIONS: These prospective data show that after an       
ACS event, patients received a regular follow-up by primary care physicians and 
cardiologists. In addition, during the year following PCI, they had planned hospital 
re-admissions but more frequently admissions related to a cardiovascular event.
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OBJECTIVES: To evaluate the effectiveness of a public tendering technique (so called 
“KIWI model”) intended to lower the price of off-patent drugs and generate a sus-
tained economy (perspective Health Insurance expenditures), applied on pharmaceu-
ticals containing simvastatin. METHODS: In 2006, the Belgian government launched 
a public tender granting a preferential reimbursement level (75/85 % reimbursed 
versus 50 %) to the company offering the lowest price for its pharmaceuticals contain-
ing simvastatin. The economy was estimated at a14.6 million for the ﬁrst year (2008 
—budget for simvastatin). Health Insurance expenses were evaluated using registered 
ﬁnancial data from NIHDI (pharmaceuticals in public pharmacies). RESULTS: In 
2008, the expenses for pharmaceuticals containing simvastatin decreased with 30% 
versus 2007 (47 versus a32.5 million). At the same time, while in 2007 the expenses 
for all statins grew with 10.5% versus 2006 (a165 versus a182 million), in 2008 the 
expenses for all statins increased only by 6.5% versus 2007 (182 versus 193.8 mio 
EURO), mainly due to an increase of the expenses for atorvastatin (16% or a85.5 
versus a99 million) and rosuvastatin (40% or a30 versus a42 million). CONCLU-
SIONS: The substantial price reductions and the estimated economy, due to the execu-
tion of the KIWI model for simvastatin, were obtained, but counterbalanced by the 
growth of the expenses for other statins. A public tendering technique for off-patent 
molecules, intending important price reductions, is therefore considerable as a means 
to control Health Insurance expenditures, if shifts versus similar (on-patent) molecules 
(therapeutic alternatives) can be mastered.
